SELLAS Announces Median Overall Survival Not Yet Reached, Now Exceeds 7.7. Months At Latest Follow-Up In The 30 Mg BIW Cohort In Patients Relapsed Or Refractory To Venetoclax-Based Regimens; Overall Response Rate Of 56% Achieved To Date In Patient...
SELLAS Announces Median Overall Survival Not Yet Reached, Now Exceeds 7.7. Months At Latest Follow-Up In The 30 Mg BIW Cohort In Patients Relapsed Or Refractory To Venetoclax-Based Regimens; Overall Response Rate Of 56% Achieved To Date In Patient...
SELLAS Announces Median Overall Survival Not Yet Reached, Now Exceeds 7.7. Months At Latest Follow-Up In The 30 Mg BIW Cohort In Patients Relapsed Or Refractory To Venetoclax-Based Regimens; Overall Response Rate Of 56% Achieved To Date In Patient With Acute Myeloid Leukemia With Myelodysplasia Related Changes Prospectively Enrolled In Two Expansion Cohorts; Exceeding Prespecified Target Response Rate Of 33%
SELLAS宣佈中位總體生存期尚未達到，最新跟進中在30毫克雙週組的患者中超過7.7個月；截至目前，在前瞻性入組的急性髓性白血病伴有骨髓發育不良相關變化的患者中，總體反應率達到56%；超出預先設定的33%的目標反應率。
- Median Overall Survival (mOS) Not Yet Reached, Now Exceeds 7.7. Months at Latest Follow-Up in the 30 mg BIW Cohort in Patients Relapsed or Refractory to Venetoclax-Based Regimens -
- 中位生存期(mOS)尚未達到，在最近的隨訪中，30 mg BIW組的患者中超過7.7個月。 -
- Overall Response Rate (ORR) of 56% Achieved to Date in Patient with Acute Myeloid Leukemia with Myelodysplasia Related Changes (AML MRC) Prospectively Enrolled in Two Expansion Cohorts; Exceeding Prespecified Target Response Rate of 33% -
- 截至目前，在急性髓性白血病伴有骨髓發育異常相關改變(AML MRC)的患者中，已達56%的總體響應率(ORR)，該患者是前瞻性登記在兩個擴展隊列中的；超過預設目標響應率33%。 -
NEW YORK, Dec. 09, 2024 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) ("SELLAS" or the "Company"), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today announced additional data from the expansion cohorts in the Phase 2 trial of SLS009, a highly selective CDK9 inhibitor, in relapsed/refractory acute myeloid leukemia (r/r AML).
紐約，2024年12月9日（全球新聞通訊）——SELLAS生命科學集團公司（納斯達克：SLS）（"SELLAS"或"公司"），是一家專注於開發廣泛癌症適應症的新型療法的晚期臨床生物製藥公司，今天宣佈來自SLS009的擴展隊列的額外數據，這是在復發/難治性急性髓性白血病（r/r AML）中使用的高度選擇性的CDK9抑制劑的第2階段試驗。
